A Phase 2 interventional study of Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium and Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium in COPD, sponsored by Verona Pharma plc. Completed at 50 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-11-20.
Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc — 1 open to participants now, 3 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Merck & Co., Inc.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 18 in phase 2, and was the 16th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 416 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 89 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Verona Pharma plc, one of the names counted as Merck & Co., Inc. Under that name alone:
Verona Pharma plc is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
1 of the studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05270525Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAEffect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium over 4 weeks of treatment. This study is intended to support optimal dose selection for a Phase III program evaluating RPL554 as an add-on treatment to standard of care therapy.
This is a Phase IIb, randomized, double-blind, placebo controlled, multiple dose, parallel group study to investigate the effects of 4 weeks of treatment with nebulized RPL554 (at different dose levels) compared to placebo in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE on a stable background therapy of open-label tiotropium. The study comprises seven visits: Pre-screening (Visit 0), Screening (Visit 1) and then a Treatment Period consisting of Randomization (Visit 2), and weekly visits for 4 weeks (Visit 3 to Visit 6).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must agree to meet the following from the first dose up to 1 month after the last dose of study medication:
If male:
If female:
Have a 12-lead recording at Screening showing the following (and no changes in the pre-dose value at the first treatment deemed by the Investigator):
Post-bronchodilator (four puffs of albuterol) spirometry at Screening demonstrating the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RPL554 0.375 mg twice daily
Drug: Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium
RPL554 0.75 mg twice daily
Drug: Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium
RPL554 1.5 mg twice daily
Drug: Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium
RPL554 3.0 mg twice daily
Drug: Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium
Placebo twice daily
Drug: Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Patients will be randomized to receive one of the following treatment arms plus tiotropiuim: ● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Least Square (LS) Mean Change From Baseline Forced Expiratory Volume in 1 Second (FEV1) to Peak FEV1 at Week 4
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and peak FEV1 was defined as the maximum value in the 3 hours after dosing. Spirometry assessments were performed in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines.
Time frame: Baseline and Week 4
LS Mean Change From Baseline FEV1 to Average Area Under the Curve Over 3 Hours (AUC0-3h) FEV1 on Day 1 and at Weeks 1 to 4
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and average AUC0-3h FEV1 was defined as area under the curve over 3 hours of the FEV1, divided by 3 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
Time frame: Baseline (30 minutes before first administration on Day 1); 30 minutes and 1, 2, and 3 hours post-dose on Day 1 and Weeks 1, 2, 3 and 4
LS Mean Change From Baseline FEV1 to Average Area Under the Curve Over 12 Hours (AUC0-12h) FEV1 on Day 1 and at Week 4
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and average AUC0-12h FEV1 was defined as area under the curve over 12 hours of the FEV1, divided by 12 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
Time frame: Baseline (30 minutes before first administration on Day 1); 30 minutes and 1, 2, 3, 4, 6, 8 and 12 hours post-dose on Day 1 and at Week 4
LS Mean Change From Baseline FEV1 to Peak FEV1 on Day 1 and at Weeks 1 to 3
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and peak FEV1 was defined as the maximum value in the 3 hours after dosing. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
Time frame: Baseline (30 minutes before first administration on Day 1); 30 minutes post-dose on Day 1 and Weeks 1, 2 and 3
LS Mean Change From Baseline FEV1 to Morning Trough FEV1 at Weeks 1 to 4
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and morning trough FEV1 was defined as the last pre-dose value. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
Time frame: Baseline (30 minutes before first administration on Day 1) and morning pre-dose on Weeks 1, 2, 3 and 4
LS Mean Change From Baseline to the Mean Weekly Evaluating Respiratory Symptoms of COPD (E-RS:COPD) Total Score at Weeks 1 to 4
The E-RS scale consists of 11 questions, with 3 sub-domains of: breathlessness, cough and sputum, and chest symptoms. The E-RS sub-domain score was calculated as the sum from the relevant questions. The E-RS:COPD scale has a scoring range of 0 to 40. Higher scores indicates severe respiratory symptoms. Baseline was the mean over the 7 days prior to first intake of study treatment. Scores were derived weekly as the mean over 7 days prior to the visit, using only days where data was recorded. The E-RS:COPD was measured by daily electronic diary (e-diary).
Time frame: Baseline and Weeks 1, 2, 3 and 4
LS Mean Change From Baseline in the St George's Respiratory Questionnaire - COPD Specific (SGRQ-C) Total Score at Weeks 2 and 4
Patients completed the SGRQ-C consisting of 40 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicated a worse outcome. The SGRQ-C was measured at Week 2 and 4 visits.
Time frame: Baseline, Weeks 2 and 4
LS Mean Transition Dyspnea Index (TDI) Questionnaire Total Score at Weeks 2 and 4
The TDI is a questionnaire that focussed on 3 sub-domains: functional impairment, magnitude of task and magnitude of effort. Sub-domain score was calculated as the sum from the related questions. Total score was calculated as the sum of the sub-domain scores. The TDI measures the change in dyspnea severity from the baseline as measured by the baseline dyspnea index. It was rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement). Higher scores indicate better outcome.
Time frame: Weeks 2 and 4
LS Mean Patient Global Assessment of Change (PGAC) Questionnaire Total Score at Weeks 2 and 4
The PGAC is a single question assessment to determine whether patients noticed a change in their breathing since the start of the study. Patients were asked to respond to a PGAC question asking, "Compared with prior to the study start, how do you feel your breathing is?" on a scale of '1=much worse' to '5=much better', with '3=no change'. Higher scores indicate better outcome.
Time frame: Weeks 2 and 4
LS Mean Change From Baseline to the Mean Weekly Values Over Weeks 1 to 4 in Number of Puffs of Rescue Medication
Use of rescue medication (albuterol) per visit was calculated as the LS mean use daily over total number of days between previous visit (inclusive) and the following visit. Baseline use was the mean over the last 7 days of the run-in phase (calculated as the sum of puffs taken, divided by number of days data has been recorded).
Time frame: Baseline and Weeks 1, 2, 3 and 4
LS Mean Change From Baseline Forced Vital Capacity (FVC) to Peak FVC on Day 1 and at Weeks 1 to 4
Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and peak FVC was defined as the maximum value in the 3 hours after dosing. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
Time frame: Baseline (30 minutes before first administration on Day 1); 30 minutes post-dose on Day 1 and Weeks 1, 2, 3 and 4
LS Mean Change From Baseline FVC to Average AUC0-3h FVC on Day 1 and at Weeks 1 to 4
Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and average AUC0-3h FVC was defined as area under the curve over 3 hours of the FVC, divided by 3 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
Time frame: Baseline (30 minutes before first administration on Day 1); 30 minutes and 1, 2, and 3 hours post-dose on Day 1 and Weeks 1, 2, 3 and 4
LS Mean Change From Baseline FVC to Average AUC0-12h FVC on Day 1 and at Week 4
Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and average AUC0-12h FVC was defined as area under the curve over 12 hours of the FVC, divided by 12 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
Time frame: Baseline (30 minutes before first administration on Day 1); 30 minutes and 1, 2, 3, 4, 6, 8 and 12 hours post-dose on Day 1 and at Week 4
LS Mean Change From Baseline FVC to Morning Trough FVC at Weeks 1 to 4
Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and morning trough FVC was defined as the last pre-dose value. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
Time frame: Baseline (30 minutes before first administration on Day 1) and morning pre-dose on Weeks 1, 2, 3 and 4
Steady-State Plasma Concentrations of Tiotropium on Day 1 and at Week 2
Blood samples were taken to determine steady-state plasma concentrations of tiotropium prior to and following 14 days of treatment with RPL554.
Time frame: Pre-dose on Day 1 and Week 2
Steady-State Plasma Concentrations of RPL554 at Week 2
Blood samples were taken to determine steady-state plasma concentrations of RPL554 following 14 days of treatment with RPL554.
Time frame: Pre-dose at Week 2
Number of Patients With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any undesirable experience occurring to a patient, or worsening in a patient, whether considered related to the study medication or not. All AEs which started after the first dose of study treatment or started prior to first dose of study treatment and worsened, based on the Investigator's assessment of severity, on or after first dose of study treatment were considered to be treatment-emergent. A serious adverse event is any adverse experience that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events.
Time frame: TEAEs were collected from the first dose of study treatment up to 1 week after the final study visit at Week 4, approximately 5 weeks.
The study was conducted at 49 study centers in the United States of America between 01 May 2019 and 15 November 2019. Overall, 416 adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) on a stable background therapy of open-label tiotropium were randomized and 413 patients received double-blind study treatment.
| Milestone | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Started | 83 | 85 | 82 | 82 | 84 |
| Received treatment | 83 | 83 | 81 | 82 | 84 |
| Completed | 73 | 70 | 75 | 76 | 79 |
| Not completed | 10 | 15 | 7 | 6 | 5 |
| Withdrew: Adverse event | 2 | 3 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 5 | 2 | 2 | 1 |
| Withdrew: Protocol violation | 5 | 6 | 4 | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 1 |
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and peak FEV1 was defined as the maximum value in the 3 hours after dosing. Spirometry assessments were performed in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines.
| liters | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Least Square (LS) Mean Change From Baseline Forced Expiratory Volume in 1 Second (FEV1) to Peak FEV1 at Week 4 | 0.1963 ± 0.02639 | 0.2100 ± 0.02676 | 0.2260 ± 0.02647 | 0.2431 ± 0.02631 | 0.1188 ± 0.02589 |
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and average AUC0-3h FEV1 was defined as area under the curve over 3 hours of the FEV1, divided by 3 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
| liters | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Day 1 | 0.1533 ± 0.01600 | 0.1614 ± 0.01602 | 0.1810 ± 0.01620 | 0.2017 ± 0.01609 | 0.0654 ± 0.01590 |
| Week 1 | 0.1118 ± 0.02129 | 0.1301 ± 0.02144 | 0.1308 ± 0.02143 | 0.1526 ± 0.02149 | 0.0246 ± 0.02107 |
| Week 2 | 0.1154 ± 0.02308 | 0.1309 ± 0.02338 | 0.1433 ± 0.02334 | 0.1651 ± 0.02321 | 0.0304 ± 0.02285 |
| Week 3 | 0.1156 ± 0.02323 | 0.1243 ± 0.02364 | 0.1444 ± 0.02343 | 0.1385 ± 0.02324 | 0.0294 ± 0.02297 |
| Week 4 | 0.1095 ± 0.02538 | 0.1305 ± 0.02574 | 0.1394 ± 0.02544 | 0.1626 ± 0.02530 | 0.0369 ± 0.02488 |
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and average AUC0-12h FEV1 was defined as area under the curve over 12 hours of the FEV1, divided by 12 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
| liters | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Day 1 | 0.0795 ± 0.01767 | 0.0909 ± 0.01770 | 0.1020 ± 0.01790 | 0.1374 ± 0.01777 | 0.0282 ± 0.01756 |
| Week 4 | 0.0359 ± 0.02455 | 0.0630 ± 0.02486 | 0.0640 ± 0.02451 | 0.0969 ± 0.02426 | 0.0096 ± 0.02413 |
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and peak FEV1 was defined as the maximum value in the 3 hours after dosing. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
| liters | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Day 1 | 0.2353 ± 0.01926 | 0.2426 ± 0.01930 | 0.2610 ± 0.01951 | 0.2852 ± 0.01938 | 0.1469 ± 0.01914 |
| Week 1 | 0.1860 ± 0.02305 | 0.2026 ± 0.02322 | 0.2116 ± 0.02321 | 0.2353 ± 0.02326 | 0.1041 ± 0.02277 |
| Week 2 | 0.1963 ± 0.02453 | 0.2121 ± 0.02483 | 0.2191 ± 0.02481 | 0.2421 ± 0.02466 | 0.1098 ± 0.02429 |
| Week 3 | 0.1987 ± 0.02503 | 0.2006 ± 0.02544 | 0.2277 ± 0.02526 | 0.2197 ± 0.02505 | 0.1072 ± 0.02476 |
Forced spirometry maneuvers including the FEV1 were used to assess pulmonary function. Baseline FEV1 was defined as the value of FEV1 assessed 30 minutes before first administration and morning trough FEV1 was defined as the last pre-dose value. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
| liters | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Week 1 | -0.0088 ± 0.02038 | -0.0354 ± 0.02058 | -0.0451 ± 0.02056 | -0.0216 ± 0.02081 | -0.0520 ± 0.02024 |
| Week 2 | -0.0278 ± 0.02183 | -0.0696 ± 0.02243 | -0.0070 ± 0.02212 | 0.0136 ± 0.02220 | -0.0377 ± 0.02169 |
| Week 3 | -0.0385 ± 0.02185 | -0.0630 ± 0.02254 | -0.0413 ± 0.02222 | -0.0232 ± 0.02205 | -0.0533 ± 0.02162 |
| Week 4 | -0.0201 ± 0.02296 | -0.0348 ± 0.02356 | -0.0141 ± 0.02311 | 0.0054 ± 0.02306 | -0.0218 ± 0.02256 |
The E-RS scale consists of 11 questions, with 3 sub-domains of: breathlessness, cough and sputum, and chest symptoms. The E-RS sub-domain score was calculated as the sum from the relevant questions. The E-RS:COPD scale has a scoring range of 0 to 40. Higher scores indicates severe respiratory symptoms. Baseline was the mean over the 7 days prior to first intake of study treatment. Scores were derived weekly as the mean over 7 days prior to the visit, using only days where data was recorded. The E-RS:COPD was measured by daily electronic diary (e-diary).
| units on a scale | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Week 1 | -0.978 ± 0.3375 | -0.669 ± 0.3375 | -0.617 ± 0.3403 | -1.142 ± 0.3405 | -0.319 ± 0.3397 |
| Week 2 | -0.873 ± 0.3916 | -0.471 ± 0.3932 | -0.597 ± 0.3921 | -0.598 ± 0.3952 | -0.102 ± 0.3908 |
| Week 3 | -0.950 ± 0.3830 | -0.338 ± 0.3865 | -1.091 ± 0.3843 | -1.097 ± 0.3827 | -0.287 ± 0.3832 |
| Week 4 | -1.690 ± 0.4337 | -0.593 ± 0.4412 | -1.226 ± 0.4346 | -1.071 ± 0.4357 | -0.228 ± 0.4320 |
Patients completed the SGRQ-C consisting of 40 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicated a worse outcome. The SGRQ-C was measured at Week 2 and 4 visits.
| units on a scale | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Week 2 | -1.808 ± 1.1960 | -1.132 ± 1.2583 | -3.465 ± 1.2311 | -3.618 ± 1.2491 | -0.249 ± 1.2277 |
| Week 4 | -4.387 ± 1.3087 | -2.400 ± 1.3732 | -4.870 ± 1.3480 | -4.163 ± 1.3479 | -0.116 ± 1.3195 |
The TDI is a questionnaire that focussed on 3 sub-domains: functional impairment, magnitude of task and magnitude of effort. Sub-domain score was calculated as the sum from the related questions. Total score was calculated as the sum of the sub-domain scores. The TDI measures the change in dyspnea severity from the baseline as measured by the baseline dyspnea index. It was rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement). Higher scores indicate better outcome.
| units on a scale | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Week 2 | 1.682 ± 0.3183 | 1.285 ± 0.3263 | 1.582 ± 0.3229 | 1.589 ± 0.3255 | 1.421 ± 0.3202 |
| Week 4 | 2.089 ± 0.3423 | 1.484 ± 0.3496 | 2.055 ± 0.3475 | 2.063 ± 0.3437 | 1.766 ± 0.3381 |
The PGAC is a single question assessment to determine whether patients noticed a change in their breathing since the start of the study. Patients were asked to respond to a PGAC question asking, "Compared with prior to the study start, how do you feel your breathing is?" on a scale of '1=much worse' to '5=much better', with '3=no change'. Higher scores indicate better outcome.
| units on a scale | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Week 2 | 3.512 ± 0.0867 | 3.522 ± 0.0895 | 3.456 ± 0.0876 | 3.523 ± 0.0889 | 3.427 ± 0.0876 |
| Week 4 | 3.553 ± 0.0922 | 3.543 ± 0.0944 | 3.536 ± 0.0932 | 3.577 ± 0.0922 | 3.506 ± 0.0909 |
Use of rescue medication (albuterol) per visit was calculated as the LS mean use daily over total number of days between previous visit (inclusive) and the following visit. Baseline use was the mean over the last 7 days of the run-in phase (calculated as the sum of puffs taken, divided by number of days data has been recorded).
| number of rescue medication puffs | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Week 1 | -0.510 ± 0.1384 | -0.580 ± 0.1407 | -0.539 ± 0.1395 | -0.629 ± 0.1412 | -0.556 ± 0.1386 |
| Week 2 | -0.325 ± 0.1822 | -0.360 ± 0.1847 | -0.388 ± 0.1828 | -0.379 ± 0.1850 | -0.544 ± 0.1812 |
| Week 3 | -0.302 ± 0.1726 | -0.139 ± 0.1765 | -0.647 ± 0.1736 | -0.558 ± 0.1742 | -0.504 ± 0.1724 |
| Week 4 | -0.412 ± 0.1753 | -0.510 ± 0.1799 | -0.784 ± 0.1766 | -0.506 ± 0.1777 | -0.671 ± 0.1741 |
Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and peak FVC was defined as the maximum value in the 3 hours after dosing. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
| liters | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Day 1 | 0.3463 ± 0.02857 | 0.3775 ± 0.02858 | 0.3852 ± 0.02892 | 0.4035 ± 0.02874 | 0.2241 ± 0.02840 |
| Week 1 | 0.2839 ± 0.03281 | 0.3199 ± 0.03302 | 0.3065 ± 0.03302 | 0.3545 ± 0.03311 | 0.1717 ± 0.03242 |
| Week 2 | 0.2597 ± 0.03401 | 0.3282 ± 0.03446 | 0.3070 ± 0.03440 | 0.3343 ± 0.03417 | 0.1524 ± 0.03368 |
| Week 3 | 0.2744 ± 0.03512 | 0.3177 ± 0.03570 | 0.3176 ± 0.03544 | 0.3008 ± 0.03513 | 0.1626 ± 0.03475 |
| Week 4 | 0.2706 ± 0.03724 | 0.3198 ± 0.03775 | 0.2951 ± 0.03729 | 0.3414 ± 0.03707 | 0.1736 ± 0.03647 |
Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and average AUC0-3h FVC was defined as area under the curve over 3 hours of the FVC, divided by 3 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
| liters | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Day 1 | 0.2165 ± 0.02390 | 0.2397 ± 0.02390 | 0.2519 ± 0.02419 | 0.2715 ± 0.02404 | 0.0864 ± 0.02375 |
| Week 1 | 0.1460 ± 0.03045 | 0.1890 ± 0.03065 | 0.1691 ± 0.03064 | 0.2039 ± 0.03074 | 0.0323 ± 0.03014 |
| Week 2 | 0.1362 ± 0.03261 | 0.2010 ± 0.03302 | 0.1783 ± 0.03296 | 0.2104 ± 0.03279 | 0.0217 ± 0.03228 |
| Week 3 | 0.1431 ± 0.03318 | 0.1860 ± 0.03372 | 0.1798 ± 0.03346 | 0.1739 ± 0.03321 | 0.0252 ± 0.03281 |
| Week 4 | 0.1350 ± 0.03606 | 0.1928 ± 0.03654 | 0.1623 ± 0.03610 | 0.2134 ± 0.03594 | 0.0382 ± 0.03533 |
Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and average AUC0-12h FVC was defined as area under the curve over 12 hours of the FVC, divided by 12 hours. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
| liters | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Day 1 | 0.0838 ± 0.02543 | 0.1294 ± 0.02543 | 0.1187 ± 0.02574 | 0.1514 ± 0.02558 | 0.0344 ± 0.02527 |
| Week 4 | 0.0152 ± 0.03486 | 0.0838 ± 0.03529 | 0.0438 ± 0.03478 | 0.0982 ± 0.03443 | -0.0030 ± 0.03425 |
Forced spirometry maneuvers including the FVC were used to assess pulmonary function. Baseline FVC was defined as the value of FVC assessed 30 minutes before first administration and morning trough FVC was defined as the last pre-dose value. Spirometry assessments were performed in accordance with ATS/ERS guidelines.
| liters | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Week 1 | -0.0159 ± 0.03028 | -0.0650 ± 0.03053 | -0.0887 ± 0.03053 | -0.0624 ± 0.03092 | -0.0617 ± 0.03008 |
| Week 2 | -0.0647 ± 0.03190 | -0.0744 ± 0.03275 | -0.0458 ± 0.03231 | -0.0045 ± 0.03245 | -0.0614 ± 0.03170 |
| Week 3 | -0.0966 ± 0.03354 | -0.0936 ± 0.03456 | -0.0857 ± 0.03410 | -0.0690 ± 0.03383 | -0.0969 ± 0.03318 |
| Week 4 | -0.0390 ± 0.03323 | -0.0347 ± 0.03408 | -0.0570 ± 0.03344 | -0.0217 ± 0.03336 | -0.0198 ± 0.03264 |
Blood samples were taken to determine steady-state plasma concentrations of tiotropium prior to and following 14 days of treatment with RPL554.
| picogram per milliliter (pg/mL) | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Day 1 | 2.8 ± 1.18 | 2.1 ± 2.98 | 1.9 ± 1.4 | 2.4 ± 3.56 | 2.4 ± 3.06 |
| Week 2 | 2.2 ± 3.85 | 2.3 ± 3.56 | 1.9 ± 1.58 | 2.0 ± 2.22 | 2.2 ± 2.13 |
Blood samples were taken to determine steady-state plasma concentrations of RPL554 following 14 days of treatment with RPL554.
| pg/mL | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Steady-State Plasma Concentrations of RPL554 at Week 2 | 37.3 ± 58.84 | 53.7 ± 51.71 | 107.9 ± 92.98 | 170.6 ± 154.3 | NA ± NA |
An adverse event (AE) was defined as any undesirable experience occurring to a patient, or worsening in a patient, whether considered related to the study medication or not. All AEs which started after the first dose of study treatment or started prior to first dose of study treatment and worsened, based on the Investigator's assessment of severity, on or after first dose of study treatment were considered to be treatment-emergent. A serious adverse event is any adverse experience that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events.
| Participants | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Any TEAE | 12 | 15 | 14 | 18 | 17 |
| Any TEAE leading to drug discontinuation | 2 | 3 | 0 | 0 | 1 |
| Any drug-related TEAE | 1 | 3 | 2 | 2 | 4 |
| Any serious TEAE | 0 | 1 | 0 | 2 | 0 |
| Any serious drug-related TEAE | 0 | 0 | 0 | 0 | 0 |
| Any serious TEAE leading drug discontinuation | 0 | 1 | 0 | 0 | 0 |
| Any TEAE leading to death | 0 | 0 | 0 | 0 | 0 |
Collected over TEAEs were collected from the first dose of study treatment up to 1 week after the final study visit at Week 4, approximately 5 weeks.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RPL554 0.375 mg | 0/82 (0%) | 0/82 (0%) | 6/82 (7.3%) |
| RPL554 0.75 mg | 0/83 (0%) | 1/83 (1.2%) | 9/83 (10.8%) |
| RPL554 1.5 mg | 0/81 (0%) | 0/81 (0%) | 4/81 (4.9%) |
| RPL554 3.0 mg | 0/83 (0%) | 2/83 (2.4%) | 8/83 (9.6%) |
| Placebo | 0/84 (0%) | 0/84 (0%) | 5/84 (6%) |
| Event | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Jaw fractureInjury, poisoning and procedural complications | 0/82 | 1/83 | 0/81 | 0/83 | 0/84 |
| SyncopeNervous system disorders | 0/82 | 0/83 | 0/81 | 1/83 | 0/84 |
| Alcohol abusePsychiatric disorders | 0/82 | 0/83 | 0/81 | 1/83 | 0/84 |
| Chronic kidney diseaseRenal and urinary disorders | 0/82 | 1/83 | 0/81 | 0/83 | 0/84 |
| Event | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo |
|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 3/82 | 2/83 | 0/81 | 3/83 | 0/84 |
| GastroenteritisInfections and infestations | 0/82 | 0/83 | 2/81 | 0/83 | 0/84 |
| HeadacheNervous system disorders | 2/82 | 1/83 | 1/81 | 2/83 | 1/84 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/82 | 1/83 | 0/81 | 2/83 | 0/84 |
| Blood creatinine increasedInvestigations | 1/82 | 2/83 | 1/81 | 0/83 | 0/84 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/82 | 2/83 | 0/81 | 0/83 | 0/84 |
| Oral candidiasisInfections and infestations | 0/82 | 1/83 | 0/81 | 1/83 | 2/84 |
| NasopharyngitisInfections and infestations | 0/82 | 0/83 | 0/81 | 1/83 | 2/84 |
All Patients Randomized Set included all patients who provided informed consent and who were randomized to study treatment.
| Age, Categorical(Participants) | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 44 | 40 | 45 | 41 | 47 | 217 |
| >=65 years | 39 | 45 | 37 | 41 | 37 | 199 |
| Age, Continuous(years) | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 64.2 ± 7.86 | 65.5 ± 8.33 | 63.8 ± 7.67 | 64.5 ± 7.92 | 63.6 ± 8.41 | 64.3 ± 8.03 |
| Sex: Female, Male(Participants) | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 51 | 48 | 51 | 45 | 44 | 239 |
| Male | 32 | 37 | 31 | 37 | 40 | 177 |
| Ethnicity (NIH/OMB)(Participants) | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 2 | 3 | 8 |
| Not Hispanic or Latino | 82 | 84 | 81 | 80 | 81 | 408 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | RPL554 0.375 mg | RPL554 0.75 mg | RPL554 1.5 mg | RPL554 3.0 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 7 | 9 | 6 | 9 | 41 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 73 | 78 | 73 | 76 | 75 | 375 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Nov 2019, 6 months.
Results were first posted in Oct 2020, 11 months after primary completion.
Of 120 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 6 months is below that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →